1. Home
  2. CTKB vs AVXL Comparison

CTKB vs AVXL Comparison

Compare CTKB & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTKB
  • AVXL
  • Stock Information
  • Founded
  • CTKB 1990
  • AVXL 2004
  • Country
  • CTKB United States
  • AVXL United States
  • Employees
  • CTKB N/A
  • AVXL 2
  • Industry
  • CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CTKB Health Care
  • AVXL Health Care
  • Exchange
  • CTKB Nasdaq
  • AVXL Nasdaq
  • Market Cap
  • CTKB 718.8M
  • AVXL 757.9M
  • IPO Year
  • CTKB 2021
  • AVXL N/A
  • Fundamental
  • Price
  • CTKB $2.93
  • AVXL $8.25
  • Analyst Decision
  • CTKB Buy
  • AVXL Strong Buy
  • Analyst Count
  • CTKB 2
  • AVXL 2
  • Target Price
  • CTKB $7.00
  • AVXL $44.00
  • AVG Volume (30 Days)
  • CTKB 659.9K
  • AVXL 675.3K
  • Earning Date
  • CTKB 05-08-2025
  • AVXL 05-13-2025
  • Dividend Yield
  • CTKB N/A
  • AVXL N/A
  • EPS Growth
  • CTKB N/A
  • AVXL N/A
  • EPS
  • CTKB N/A
  • AVXL N/A
  • Revenue
  • CTKB $197,050,000.00
  • AVXL N/A
  • Revenue This Year
  • CTKB $4.02
  • AVXL N/A
  • Revenue Next Year
  • CTKB $8.47
  • AVXL N/A
  • P/E Ratio
  • CTKB N/A
  • AVXL N/A
  • Revenue Growth
  • CTKB N/A
  • AVXL N/A
  • 52 Week Low
  • CTKB $3.27
  • AVXL $3.51
  • 52 Week High
  • CTKB $7.63
  • AVXL $14.44
  • Technical
  • Relative Strength Index (RSI)
  • CTKB 26.81
  • AVXL 40.05
  • Support Level
  • CTKB $3.64
  • AVXL $8.20
  • Resistance Level
  • CTKB $3.89
  • AVXL $8.81
  • Average True Range (ATR)
  • CTKB 0.18
  • AVXL 0.41
  • MACD
  • CTKB -0.02
  • AVXL -0.12
  • Stochastic Oscillator
  • CTKB 5.08
  • AVXL 3.13

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Share on Social Networks: